Biomind Labs Statistics
Total Valuation
Biomind Labs has a market cap or net worth of 19.42 million. The enterprise value is 20.24 million.
| Market Cap | 19.42M |
| Enterprise Value | 20.24M |
Important Dates
The next estimated earnings date is Monday, November 16, 2026.
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biomind Labs has 77.57 million shares outstanding. The number of shares has increased by 0.03% in one year.
| Current Share Class | 77.57M |
| Shares Outstanding | 77.57M |
| Shares Change (YoY) | +0.03% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 36.31% |
| Owned by Institutions (%) | n/a |
| Float | 49.41M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -10.21 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.00
| Current Ratio | 0.00 |
| Quick Ratio | 0.00 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -3.56 |
| Interest Coverage | -19.47 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -8,087.24% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 72.31% |
| Weighted Average Cost of Capital (WACC) | 42.77% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +1,484.18% in the last 52 weeks. The beta is 7.28, so Biomind Labs's price volatility has been higher than the market average.
| Beta (5Y) | 7.28 |
| 52-Week Price Change | +1,484.18% |
| 50-Day Moving Average | 0.20 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 48.60 |
| Average Volume (20 Days) | 11,851 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 9.94 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -1.38M |
| Pretax Income | -1.45M |
| Net Income | -1.45M |
| EBITDA | -1.37M |
| EBIT | -1.38M |
| Earnings Per Share (EPS) | -0.02 |
Balance Sheet
The company has 35 in cash and 828,718 in debt, with a net cash position of -828,683 or -0.01 per share.
| Cash & Cash Equivalents | 35 |
| Total Debt | 828,718 |
| Net Cash | -828,683 |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | -1.90M |
| Book Value Per Share | -0.02 |
| Working Capital | -1.90M |
Cash Flow
| Operating Cash Flow | -232,648 |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 1,115 |
| Net Borrowing | 209,233 |
| Free Cash Flow | -232,648 |
| FCF Per Share | -0.00 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Biomind Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.03% |
| Shareholder Yield | -0.03% |
| Earnings Yield | -7.49% |
| FCF Yield | -1.20% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |